Evidence for the involvement of opioid and cannabinoid systems in the peripheral antinociception mediated by resveratrol

Página do item simplificado
dc.creatorCristina da Costa Oliveira
dc.creatorMarina Gomes Miranda e Castor
dc.creatorCamila Gomes Miranda e Castor
dc.creatorÁghata de França Costa
dc.creatorRenata Cristina Mendes Ferreira
dc.creatorJosiane Fernandes da Silva
dc.creatorJuliana Maria Navia Pelaez
dc.creatorLuciano dos Santos Aggum Capettini
dc.creatorVirginia Soares Lemos
dc.creatorIgor Dimitri Gama Duarte
dc.creatorAndrea de Castro Perez
dc.creatorSergio Henrique Sousa Santos
dc.creatorThiago Roberto Lima Romero
dc.date.accessioned2022-08-29T14:28:45Z
dc.date.accessioned2025-09-08T23:56:24Z
dc.date.available2022-08-29T14:28:45Z
dc.date.issued2019-04-15
dc.description.sponsorshipCNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológico
dc.description.sponsorshipFAPEMIG - Fundação de Amparo à Pesquisa do Estado de Minas Gerais
dc.description.sponsorshipCAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
dc.identifier.doihttps://doi.org/10.1016/j.taap.2019.02.004
dc.identifier.issn0041-008X
dc.identifier.urihttps://hdl.handle.net/1843/44653
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofToxicology and Applied Pharmacology
dc.rightsAcesso Restrito
dc.subjectOpióides
dc.subjectCanabinóides
dc.subjectFitonutrientes
dc.subjectHiperalgesia
dc.titleEvidence for the involvement of opioid and cannabinoid systems in the peripheral antinociception mediated by resveratrol
dc.typeArtigo de periódico
local.citation.epage38
local.citation.spage30
local.citation.volume369
local.description.resumoDespite all the development of modern medicine, around 100 compounds derived from natural products were undergoing clinical trials only at the end of 2013. Among these natural substances in clinical trials, we found the resveratrol (RES), a pharmacological multi-target drug. RES analgesic properties have been demonstrated, although the bases of these mechanisms have not been fully elucidated. The aim of this study was to evaluate the involvement of opioid and cannabinoid systems in RES-induced peripheral antinociception. Paw withdrawal method was used and hyperalgesia was induced by carrageenan (200 μg/paw). All drugs were given by intraplantar injection in male Swiss mice (n = 5). RES (100 μg/paw) administered in the right hind paw induced local antinociception that was antagonized by naloxone, non-selective opioid receptor antagonist, and clocinnamox, μOR selective antagonist. Naltrindole and nor-binaltorfimine, selective antagonists for δOR and kOR, respectively, did not reverse RES-induced peripheral antinociception. CB1R antagonist AM251, but not CB2R antagonist AM630, antagonized RES-induced peripheral antinociception. Peripheral antinociception of RES intermediate-dose (50 μg/paw) was increased by: (i) bestatin, inhibitor of endogenous opioid degradation involved-enzymes; (ii) MAFP, inhibitor of anandamide amidase; (iii) JZL184, inhibitor of 2-arachidonoylglycerol degradation involved-enzyme; (iv) VDM11, endocannabinoid reuptake inhibitor. Acute and peripheral administration of RES failed to affect the amount of μOR, CB1R and CB2R. Experimental data suggest that RES induces peripheral antinociception through μOR and CB1R activation by endogenous opioid and endocannabinoid releasing.
local.publisher.countryBrasil
local.publisher.departmentICA - INSTITUTO DE CIÊNCIAS AGRÁRIAS
local.publisher.initialsUFMG
local.url.externahttps://www.sciencedirect.com/science/article/pii/S0041008X19300535

Arquivos

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG